Int'l : +1(646) 600-5072 | query@kbvresearch.com
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Asia Pacific Pharmacogenomics Market, published by KBV research, the Asia Pacific Pharmacogenomics Market would witness market growth of 10.2% CAGR during the forecast period (2019-2025).
The Oncology market dominated the Singapore Pharmacogenomics Market by Application in 2018, growing at a CAGR of 10.3 % during the forecast period. The Psychiatry market is expected to witness a CAGR of 11.4% during (2019 - 2025).
The Hospitals and Clinics market dominated the Asia Pacific Pharmacogenomics Market by End User in 2018, growing at a CAGR of 9.9 % during the forecast period. The Research Institutions market is expected to witness highest CAGR of 10.6% during (2019 - 2025).
The China market dominated the Asia Pacific Sequencing Market by Country in 2018, thereby, achieving a market value of $89.2 million by 2025, growing at a CAGR of 7.1 % during the forecast period. The Japan market is expected to witness a CAGR of 10.4% during (2019 - 2025). Additionally, The India market is expected to witness a CAGR of 10.4% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/asia-pacific-pharmacogenomics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
By Technology
By Application
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research